Evolus vs Harrow
EOLS and HROW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EOLS and HROW compare
Harrow is the larger company, worth 2.5 times as much as Evolus ($1.1B against $460M).
Harrow grew revenue faster over the last twelve months (21.3% versus 13.9% for Evolus).
Harrow keeps more of each dollar of sales as profit, with a net margin of −9.4% compared with −9.6% at Evolus.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EOLS | HROW |
|---|---|---|
| Size and price | ||
| Market cap | $460M | $1.1B |
| Share price | $6.96 | $30.12 |
| Change, 1 year | −4.7% | −21.6% |
| Change, 5 years | 9.1% | 179% |
| Beta (5Y) | 1.13 | 1.37 |
| Employees | 334 | 373 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 2 | 2 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× (better) | 3.7× |
| P/B | – | 38.7× |
| FCF yield | −1.1% (better) | −1.8% |
| Growth | ||
| Revenue growth (TTM) | 13.9% | 21.3% (better) |
| Revenue growth, 5Y average | 39.4% | 41.0% (better) |
| Profitability | ||
| Gross margin | 66.4% | 73.5% (better) |
| Operating margin | −4.8% | −2.0% (better) |
| Net margin | −9.6% | −9.4% (better) |
| FCF margin | −1.5% (better) | −6.7% |
| Return on equity | – | −74.8% |
| Return on invested capital | −16.3% | −2.1% (better) |
| Financial health | ||
| Debt / equity | – | 10.03 |
| Interest coverage | −1.0× | −0.3× (better) |
| Current ratio | 1.42 | 2.29 (better) |
| Altman Z-score | −1.34 | 2.07 (better) |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.0% | 57.4% |
| Held by insiders | 4.1% | 14.2% |
| Insider net buying, 12 months | −$1.8M (better) | −$9.2M |
| Short interest, % of float | 9.5% | 22.1% |
Go deeper
- EOLS stock overview
- EOLS income statement
- EOLS valuation and score
- HROW stock overview
- HROW income statement
- HROW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.